Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no visible changes to core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision metadata updated from v3.4.0 to v3.4.1; no study details or user-facing functionality were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded a glossary toggle and updated page metadata to include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4 with no changes to the clinical study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check71 days agoChange DetectedThe Locations section now includes a new Illinois site. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check93 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.3.1 has been removed.SummaryDifference0.0%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.